PMAM
DNTH icon

Picton Mahoney Asset Management’s Dianthus Therapeutics DNTH Stock Holding History

Picton Mahoney Asset Management’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-455
Closed -$8K – 1025
2025
Q1 		$8K Buy
+455
New +$10K ﹤0.01% 633

Other funds holding DNTH

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Picton Mahoney Asset Management's DNTH Position: Q2 2025 in Review

Picton Mahoney Asset Management sold out of Dianthus Therapeutics (DNTH) in Q2 2025, closing a stake of 455 shares — an estimated $8K sold.

Picton Mahoney Asset Management first reported a position in DNTH in Q1 2025 and held it in 1 quarter. The position peaked at $8K in Q1 2025. 102 funds tracked by Wall St. Rank hold DNTH as of Q2 2025.

  • Picton Mahoney Asset Management reported no remaining Dianthus Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Picton Mahoney Asset Management sold 455 Dianthus Therapeutics shares in Q2 2025, an estimated $8K.
  • Picton Mahoney Asset Management first reported a position in Dianthus Therapeutics in Q1 2025 and held it in 1 quarter.
  • Picton Mahoney Asset Management's Dianthus Therapeutics position peaked at $8K in Q1 2025.
  • 102 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2025.

Based on Picton Mahoney Asset Management's 13F filing for Q2 2025, filed 12 Aug 2025.